FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:816-821 March 22, 1990 Number 12 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To compare ondansetron (GR 38032F), a 5-hydroxytryptamine3-receptor antagonist, with metoclopramide in the prophylaxis of acute cisplatin-induced emesis, we conducted a double-blind crossover study in 97 patients scheduled to receive cisplatin (80 to 100 mg per square meter of body-surface area) for treatment of cancer. None had received chemotherapy before this trial. Among the 76 patients who satisfactorily completed both parts of the study, complete or nearly complete control of emesis (i.e., no episodes of emesis occurred, or only one or two) was achieved in 57 of 76 treatments (75 percent) with ondansetron and in 32 of 76 treatments (42 percent) with metoclopramide (P less than 0.001). Ondansetron was also more effective in controlling acute nausea, as assessed with a visual-analogue scale (P = 0.019) or a graded scale (P = 0.024). There was a significant preference among patients for ondansetron (55 vs. 26 percent; P = 0.006). Dystonic reactions were observed during three treatments with metoclopramide; both agents were otherwise well tolerated. We conclude that ondansetron is more effective than metoclopramide in the control of cisplatin-induced nausea and vomiting, and that this suggests that serotonin is an important mediator of this side effect.

Source Information

Service d'Oncologie Medicale, Hopital St. Louis, Paris, France.

This article has been cited by other articles:

• Herrstedt, J., Apornwirat, W., Shaharyar, A., Aziz, Z., Roila, F., Van Belle, S., Russo, M. W., Levin, J., Ranganathan, S., Guckert, M., Grunberg, S. M. (2009). Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy. JCO 27: 5363-5369 [Abstract] [Full Text]  
• Wood, G. J., Shega, J. W., Lynch, B., Von Roenn, J. H. (2007). Management of Intractable Nausea and Vomiting in Patients at the End of Life: "I Was Feeling Nauseous All of the Time . . . Nothing Was Working". JAMA 298: 1196-1207 [Abstract] [Full Text]  
• Kris, M. G., Hesketh, P. J., Somerfield, M. R., Feyer, P., Clark-Snow, R., Koeller, J. M., Morrow, G. R., Chinnery, L. W., Chesney, M. J., Gralla, R. J., Grunberg, S. M. (2006). American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. JCO 24: 2932-2947 [Abstract] [Full Text]  
• Schnell, F. M. (2003). Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control. The Oncologist 8: 187-198 [Abstract] [Full Text]  
• Kwon, K. T., Rudkin, S. E., Langdorf, M. l. (2002). Antiemetic Use in Pediatric Gastroenteritis: A National Survey of Emergency Physicians, Pediatricians, and Pediatric Emergency Physicians. CLIN PEDIATR 41: 641-652 [Abstract]  
• Goodin, S., Cunningham, R. (2002). 5-HT3-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile. The Oncologist 7: 424-436 [Abstract] [Full Text]  
• Emanuel, E. J., Miller, F. G. (2001). The Ethics of Placebo-Controlled Trials -- A Middle Ground. NEJM 345: 915-919 [Full Text]  
• Emanuel, E. J., Wendler, D., Grady, C. (2000). What Makes Clinical Research Ethical?. JAMA 283: 2701-2711 [Abstract] [Full Text]  
• Yamakuni, H., Sawai, H., Maeda, Y., Imazumi, K., Sakuma, H., Matsuo, M., Mutoh, S., Seki, J. (2000). Probable Involvement of the 5-Hydroxytryptamine4 Receptor in Methotrexate-Induced Delayed Emesis in Dogs. J. Pharmacol. Exp. Ther. 292: 1002-1007 [Abstract] [Full Text]  
• Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., Koeller, J. M., Morrow, G. R., Perez, E. A., Silber, J. H., Pfister, D. G. (1999). Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. JCO 17: 2971-2971 [Full Text]  
• Tomioka, S., Kurio, T., Takaishi, K., Nakajo, N. (1999). Propofol Is Effective in Chemotherapy-Induced Nausea and Vomiting: A Case Report with Quantitative Analysis. Anesth. Analg. 89: 798-798 [Full Text]  
• Vermeulen, L. C. Jr, Matuszewski, K. A., Ratko, T. A., Butler, C. D., Burnett, D. A., Vlasses, P. H. (1994). Evaluation of Ondansetron Prescribing in US Academic Medical Centers. Arch Intern Med 154: 1733-1740 [Abstract]  
• Grunberg, S. M., Hesketh, P. J. (1993). Control of Chemotherapy-Induced Emesis. NEJM 329: 1790-1796 [Full Text]  
• Herrstedt, J., Sigsgaard, T., Boesgaard, M., Jensen, T. P., Dombernowsky, P. (1993). Ondansetron plus Metopimazine Compared with Ondansetron Alone in Patients Receiving Moderately Emetogenic Chemotherapy. NEJM 328: 1076-1080 [Abstract] [Full Text]  
• Levitt, M., Warr, D., Yelle, L., Rayner, H. L., Lofters, W. S., Perrault, D. J., Wilson, K. S., Latreille, J., Potvin, M., Warner, E., Pritchard, K. I., Palmer, M., Zee, B., Pater, J. L. (1993). Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil. NEJM 328: 1081-1084 [Abstract] [Full Text]  
• De Mulder, P. H. M., Seynaeve, C., Vermorken, J. B., van Liessum, P. A., Mols-Jevdevic, S., Allman, E. L., Beranek, P., Verweij, J. (1990). Ondansetron Compared with High-Dose Metoclopramide in Prophylaxis of Acute and Delayed Cisplatin-Induced Nausea and Vomiting: A Multicenter, Randomized, Double-Blind, Crossover Study. ANN INTERN MED 113: 834-840 [Abstract]  
• (1990). NEW POWERFUL ANTIEMETICS: SEROTONIN-RECEPTOR BLOCKERS. JWatch General 1990: 2-2 [Full Text]